A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma

NCT01865747 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

658

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Cabozantinib tablets
DRUG: Everolimus (Afinitor) tablets

Sponsor

Exelixis